NEX-I debuts on KOSDAQ after cut-price $29.9M IPO
What's the deal? Immuno-oncology drug developer NEX-I lists on South Korea's KOSDAQ market today, November 12, raising US$33.5M (roughly $29.9 million) by selling 5 million new shares. At its confirmed offer price, the company carries an expected market capitalisation of about US$307.5M. Korea Investment & SecuritiesDealroom has a profile for this one. Try Dealroom → led the offering.
Why the discount? The final offer price of US$6.71 landed about 23.8% below the bottom of the US$8.8–US$10.9 indicative range. Institutional demand was thin: 506 institutions produced a 66.58-to-1 competition ratio, with mandatory holding commitments at just 0.06% of applied volume. Retail subscriptions drew a 13.26-to-1 ratio.
What's the endgame? Founded in 2021, NEX-I develops antibody drugs for cancers that resist immunotherapy, built on its proprietary NEXORA platform. Proceeds will fund clinical trials of lead candidate NXI-201 — now entering Phase 1/2 in the US and Korea — plus research on follow-on candidates, including antibody-drug conjugates and a bispecific antibody.
The track record: NEX-I's standout credential is a 2024 deal licensing candidate NXI-101 to Japan's Ono PharmaceuticalDealroom has a profile for this one. Try Dealroom →, maker of checkpoint inhibitor Opdivo. The agreement validated the platform's commercial potential, though NXI-101 remains in early-stage testing.
The numbers: NEX-I posted an operating loss of US$13.8M last year, swinging to a deficit as R&D and trial costs mounted. That burn is typical for a clinical-stage biotech, but it sharpens the pressure on NEX-I to deliver trial results and additional licensing deals.
What could go wrong? The company's valuation assumes it can repeat the NXI-101 dealmaking across its pipeline. "We will grow into a global drug developer through continued technology transfers," chief executive officer Yoon Kyung-wan said — but clinical progress and further deals remain unproven.
The signal: The steep pricing cut and weak institutional demand show investors remain cautious on clinical-stage biotech, even for a developer with a global licensing deal already in hand. NEX-I's debut is less a test of whether such firms can list than a gauge of how the market prices high clinical and funding uncertainty.
Read more: edaily.co.kr
Image credit: Generated with Gemini
